DR. RAHUL NARAYAN MADDI

• MBBS from Rajiv Gandhi University of Health Sciences – 2005 – Karnataka
• MD General Medicine from Manipal Academy of Higher Education – 2009 – Karnataka
• DM – Medical Oncology from Nizam Institute of Medical Sciences – 2013 – Hyderabad
• Senior Resident at AIG Hospitals

• Cancer Treatment/Therapies in Medical Oncology
• Chemotherapy
• Targeted Therapy/Precision Oncology
• Head and Neck Cancer Treatment (Oral Cancer/Buccal Mucosa Cancer/Throat Cancer/Larynx Cancer/Hypopharynx Cancer)
• Breast Cancer Treatment
• Solid Tumors (Breast Cancer, Lung Cancer, Gastrointestinal Cancer (Pancreatic Cancer, Gallbladder Cancer, Colon/Intestinal Cancer), Sarcoma, Bone Cancer, Gynecological Cancers (Cervical Cancer, Uterine Cancer, Ovarian Cancer), Genitourinary Cancer (Testicular Cancer, Bladder Cancer, Prostate Cancer), Medical Oncology, Management of Brain Tumors
• Pediatric Oncology/Childhood Cancers
• Supportive and Palliative Care
• Cancer Nutrition
• Cancer Survivorship

• Immunotherapy
• Hematological Malignancies/Blood Cancers/Lymphoma/Leukemia/Multiple Myeloma
• Solid Tumors
• Pediatric Oncology
• Cancer Nutrition
• Precision Oncology

• First and foremost, Dr.Rahul has given more than 40000 chemotherapies during his tenure at Raksha Cancer Hospital in Karimnagar.
• Management of various solid and haematological malignancies in adult and pediatric patients.
• Well-versed with various frontline protocols like FAC, CMF, AT, AC+T for breast cancer
• Platinum-based regimens for lung, testicular and ovarian cancers; P+F, TIP for head and neck cancers; FOLFOX, FOLFIRI, CAPOX, CAPIRI etc. for colorectal cancers; concurrent chemo-radiation protocols for head and neck, oesophageal and anal canal/rectal cancers
• Experience with newer molecules like Rituximab, Cetuximab, Herceptin, Perjeta, Kadcyla, Bevacizumab, Velcade, Carfilzomib,, Daratumumab, Denosumab etc.
• Insertion, maintenance of chemo ports, central catheters, PICCs, Omaya reservoirs etc.
• Well-versed and trained in multiple Immunotherapies like Pembrolizumab, Nivolumab and Atezulizumab etc
• Have almost more than 300 patients on Glivec/Imatinib with excellent compliance and complete molecular response.
• Induction Protocols in Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia. In cases where induction is not possible due to financial constraints or fitness issues we prefer treating with Azacytidine or Decitabine + Venetoclax rather than leaving the patient alone.
• ABVD, COPP, BFM 86, hyper CVAD, CODOX-M/IVAC, FLAG, FLAG-Ida, DHAP, ASHAP, ESHAP, R-ICE protocols for relapsed leukemias and lymphomas
• High dose Ifosfamide / Cyclophosphamide and High dose Methotrexate based regimens for sarcomas (soft tissue and bone).

Speaker

Latest updates in Medical Oncology and Targetted therapies, Zonal CME, CAIMS Cancer hospital and research center, Karimnagar, 2014

Speaker

Tumour markers and their utility in Oncology, 2014, Indian Medical association, Karimnagar

Speaker

Targetted therapies in Oncology, Indian Medical Association, Jagityal, 2014

Speaker

Cancer screening and early detection, Indian Medical Association, Koratla, 2014

Speaker

Curable malignancies, Indian Medical Association, Sircilla, 2015

Speaker

Neoadjuvant Chemotherapy in Gastric Cancer, ASICON, Karimnagar 2018

Speaker

Pediatric Malignancies and Curability, 5^th ANNUAL CONFERENCE OF PEDIATRIC ACADEMY OF TELANGANA(PATS) 2019

 Speaker

CML, a classical case of Targetted therapy, IMA, Karimanagar

Speaker

Monoclonal Antibodies in Oncology, APICON, Karimnagar 2020

Speaker

Chronic Leukaemia overview and treatments, Dr.NTRUHS ZONAL CME, Dept of General Medicine, 2014

Speaker

Lung Cancer and Targetted therapy, Pulmonology meet 2019, Karimnagar

Speaker

Judicious use of PET CT scan in Oncology, IMA, Jagityal

Chair person

Curable Maligancies, An Insight, 2019, APICON, Karimnagar

Chair Person

Targetted therapy in Breast Cancer, November 2022

Speaker

Molecular Biology in Lung Cancer and its Importance, PULMOCON, 2023

• An anthropometric study in children with chronic myeloid leukemia on imatinib.Presented as poster at ASCO, Chicago, USA. June 1-5, 2012, Rahul Narayan Maddi, Vamshi Krishna Goteke, Narender Kumar Thota, Pragnya Coca, Balakrishna Nagalla, Vijay Gandhi Linga, Sadashivudu Gundeti, Raghunadharao Digumarti; Nizam’s Institute of Medical Sciences, Hyderabad, India; Department of Medical Oncology, Hyderabad, India; National Institute of Nutrition, Hyderabad, India
• Clinical profile and outcome of adult Hodgkin Lymphoma: Experience from a tertiary care institution, Rahul Narayan Maddi , Vijay Gandhi Linga , Kalpathi Krishnamani Iyer , Joseph Stalin Chowdary , Sadashivudu Gundeti , Raghunadharao Digumarti , Tara Roshini Paul, Department of Medical Oncology, Chalmeda Anand Rao Institute of Medical Sciences, Karimnagar, 2 Director and Department of Medical Oncology, Tata Memorial Center, Vishakapatnam, Andhra Pradesh, Departments of 1 Medical Oncology and 3 Pathology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India
• Secondary malignancies in CML patients- a retrospective analysis from a tertiary care centre in India, Rahul Narayan Maddi , Vijay Gandhi Linga , Kalpathi Krishnamani Iyer , Joseph Stalin Chowdary , Sadashivudu Gundeti , Raghunadharao Digumarti
• Outcome of pregnancy in women on imatinib for CML. Rahul Narayan Maddi , Vijay Gandhi Linga, Kalpathi Krishnamani Iyer , Joseph Stalin Chowdary , Sadashivudu Gundeti , Raghunadharao Digumarti ,
• Long term outcome of paediatric hodgkin lymphoma – a two decade experience, Rahul Narayan Maddi , Vijay Gandhi Linga , Kalpathi Krishnamani Iyer , Joseph Stalin Chowdary , Sadashivudu Gundeti , Raghunadharao Digumarti ,
• CHOP chemotherapy plus rituximab compared with CHOP alone in patients with diffuse large B-cell lymphoma, from Indian subcontinent. Rahul Narayan Maddi , Vijay Gandhi Linga , Kalpathi Krishnamani Iyer , Joseph Stalin Chowdary , Sadashivudu Gundeti , Raghunadharao Digumarti
• Outcome of Patients on First Line PemetrexedDoublet in Advanced Stage Adenocarcinoma of Lung Rahul Narayan Maddi, Vamshi Krishna Reddy G, Pragnya Coca,
• Poster presentation at Mumbai Lymphomas and Leukemias 2012, 6-8, January 2012

• July to October 2009: Consultant physician at Apollo Reach Hospital, Karimnagar
• Sept 2013 to August 2022.Worked as Chief Medical Oncologist at Raksha Cancer Hospital & Chemotherapy Center, Karimnagar
• 2013 -2016 Worked as assistant professor and Head of the Dept of Medical Oncology, Chelmeda Cancer Hospital, Karimnagar.
• Sept 2022- Present: Director, Chief Medical Oncologist, Prathima Cancer Institute, Warangal.

• Young Medical Oncologists meet 2010, Hyderabad.
• Young Medical Oncologists Meet, 2011, Hyderabad.
• 43rd Annual Congress, SIOP at Boston, USA International society of pediatric oncology, Boston, USA 27th– 30^th Oct, 2011.
• Annual Conference of ASCO at Chicago, USA American Society of Clinical Oncology, USA June 3 – 7, 2012.
• Lymphomas and leukemias 2012, Mumbai, India 6-8 Jan, 2012.
• ISMPO Meet 2012 Vishakhapatnam, Andhra Pradesh , India February 2012.
• Global oncology summit GENOME, December 2014, Singapore.